Enhanced and complementary benefits of a nalfurafine and fingolimod combination to treat immune-driven demyelination.

Robichon, Katharina; Bibi, Rabia; Kiernan, Mackenzie; Denny, Lisa; Prisinzano, Thomas E; Kivell, Bronwyn M; La Flamme, Anne Camille

Enhanced and complementary benefits of a nalfurafine and fingolimod combination to treat immune-driven demyelination.

Robichon, Katharina; Bibi, Rabia; Kiernan, Mackenzie; Denny, Lisa; Prisinzano, Thomas E; Kivell, Bronwyn M; La Flamme, Anne Camille.

Afiliación

Robichon K; School of Biological Sciences Victoria University of Wellington Wellington New Zealand.
Bibi R; Centre for Biodiscovery Wellington Victoria University of Wellington Wellington New Zealand.
Kiernan M; School of Biological Sciences Victoria University of Wellington Wellington New Zealand.
Denny L; Centre for Biodiscovery Wellington Victoria University of Wellington Wellington New Zealand.
Prisinzano TE; School of Biological Sciences Victoria University of Wellington Wellington New Zealand.
Kivell BM; Centre for Biodiscovery Wellington Victoria University of Wellington Wellington New Zealand.
La Flamme AC; School of Biological Sciences Victoria University of Wellington Wellington New Zealand.

Clin Transl Immunology ; 12(12): e1480, 2023.

Article en En | MEDLINE | ID: mdl-38090669

Palabras clave

experimental autoimmune encephalomyelitis; fingolimod; kappa opioid receptor agonist; nalfurafine; neuroinflammation; remyelination

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Clin Transl Immunology Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Clin Transl Immunology Año: 2023 Tipo del documento: Article